Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26366626
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Hydroxyurea therapy for sickle cell anemia
#MMPMID26366626
McGann PT
; Ware RE
Expert Opin Drug Saf
2015[]; 14
(11
): 1749-58
PMID26366626
show ga
INTRODUCTION: Sickle cell anemia (SCA) is a severe, inherited hemoglobin disorder
affecting 100,000 persons in the US and millions worldwide. Hydroxyurea, a once
daily oral medication, has emerged as the primary disease-modifying therapy for
SCA. The accumulated body of evidence over 30 years demonstrates that hydroxyurea
is a safe and effective therapy for SCA, but hydroxyurea remains underutilized
for a variety of reasons. AREAS COVERED: In this review, we summarize the
available evidence regarding the pharmacology, clinical, and laboratory benefits,
and safety of hydroxyurea therapy for the treatment of SCA. The purpose of this
review is to provide the reader a comprehensive understanding of hydroxyurea and
to reinforce the fact that hydroxyurea is a safe and effective medication for the
treatment of SCA. EXPERT OPINION: In our opinion, hydroxyurea therapy should be
considered standard-of-care for SCA, representing an essential component of
patient management. Early initiation and broader use of hydroxyurea will alter
the natural history of SCA, so affected children can live longer and healthier
lives. In addition, hydroxyurea use should be extended to low-resource settings
such as sub-Saharan Africa, where the burden of SCA and the need for hydroxyurea
is arguably the greatest.
|Administration, Oral
[MESH]
|Anemia, Sickle Cell/*drug therapy
[MESH]
|Animals
[MESH]
|Antisickling Agents/administration & dosage/adverse effects/*therapeutic use
[MESH]
free
free
free
